The Limited Times

Now you can see non-English news...

Vaccines: to bring Pfizer Argentina now seeks to contract IDB insurance

2021-06-20T01:38:55.131Z


The multilateral organization offers a financial instrument to their countries for the Covid. "We are on the right track," said Deputy Massa in the United States.


Paula Lugones

06/16/2021 18:30

  • Clarín.com

  • Economy

Updated 06/16/2021 18:30

The head of the Chamber of Deputies,

Sergio Massa

, seeks in Washington a way out to

unblock

the

donation of millions of vaccines that the United States offers to the world

and that cannot reach Argentina due to legal obstacles. For this, Massa explores an instrument of the Inter-American Development Bank (IDB) that offers countries a kind of

"indemnity insurance"

that could thus speed up the contracts of US laboratories in our country such as Pfizer.

The Joe Biden government announced weeks ago that the United States would donate 6 million doses to Latin America (out of a total of 25 million) and that

Argentina and Brazil, among other countries in the region

, are on the list of chosen.

The White House has not yet announced the amount it will distribute to each nation through the Covax mechanism, although it is estimated that communication will be imminent.

Massa is the highest-level leader of the Alberto Fernández government who has so far arrived in Washington.

He landed here on Sunday with the mission of oiling bilateral relations, obtaining political support for negotiations with the IMF and seeking to expedite the donation of vaccines that would befall Argentina, among the most important issues.

For Argentina, the issue of the delivery of vaccines can have complications because beyond the Biden government's vocation to donate them, the Government has not signed a contract with Pfizer, Moderna and Johnson & Johnson, the three brands that the US has. It is offering.

The last two were not even approved by ANMAT.

As is known, Pfizer has had serious difficulties in negotiating a legal document because Argentina wanted to include negligence as an exception to the compensation requested by the laboratories.

It doesn't seem like it was going to be fixed.

But this IDB instrument could be a way out.

Asked by

Clarín

on the subject, Massa was somewhat enigmatic, but he did not deny it:

“On the subject of vaccines, intelligence must be used so that the difficulties that a vaccine provider may feel in the regulatory framework are resolved thanks to those of us who have the responsibility to do.

But I have no doubt that we are on the right track, "he

said.

But

Clarín

learned that the dialogue on the subject is directed with officials of the IDB in an underground way because the Government of Alberto Fernández does not have great harmony with the president of the organization,

Mauricio Claver Carone

, who last year drowned the aspirations of the Argentine candidate Gustavo Béliz to the head of the multilateral.

But Claver Carone is a pragmatist and needs to show results in his presidency, in addition to

rebuilding the relationship with Argentina for eventual support in the recapitalization of the body

.

The instrument that Argentina is looking for, which is like an

"insurance policy,"

had been publicly announced by Carone himself in a virtual press conference in

March

, where he explained that one of the reasons for the delay in vaccination in less wealthy countries These are the conditions that laboratories ask for in order to sign contracts.

"We realized that the pharmaceutical companies were asking for indemnity clauses in the negotiations, to which many other things were added later, such as the creation of trusts to guarantee any liability problems, and now we see that they are even asking for

new regulatory frameworks

", Claver then said.

“What we are announcing today,” he continued, “is a financial instrument that will serve as a guarantee for the terms and conditions in which the vaccines are delivered, in the event of any contingency.

The IDB is the first international financial institution to create a product of this type ”.

“It is like an insurance policy, both for countries and for pharmaceutical companies, which are asking for certain liability provisions.

As this is difficult for the states due to their legal frameworks or because they have never done it, what we offer is an instrument that provides that guarantee in case the liability clauses are activated ”, he explained.

It is not yet known how many doses will touch Argentina in the United States, but in Massa's delegation they are enthusiastic that it may be "more than a million."

They will not be delivered immediately and it is estimated that they will be available from August at the earliest.

But, in the meantime, legal obstacles can be resolved so as not to lose the opportunity of the most precious asset at this time.

Source: clarin

All business articles on 2021-06-20

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.